Seasonal #Influenza #Exposure Elicits Functional #Antibody and T-cell Responses to #H5 Influenza Viruses in #Humans

Abstract

Background.

Highly pathogenic avian influenza A(H5) viruses pose a pandemic threat, with a history of zoonotic spillovers into humans that are presumed immunologically naive. Whether the general population is currently immunologically naive to circulating A(H5) influenza viruses is unknown.

Methods.

To evaluate the presence of cross-reactive immune responses to emerging A(H5) clade 2.3.4.4b influenza viruses in the general population, we conducted comprehensive immune profiling on cross-sectional samples from healthcare workers (n=107). Samples were collected in August and September 2024 in the scope of an ongoing prospective follow-up study: Surveillance of rEspiratory viruses iN healThcare and anImal workers in the NethErLands (SENTINEL).

Findings.

Low-level antibody responses directed against the A(H5) hemagglutinin (HA) head were detected in a limited number of individuals, but without hemagglutination inhibition activity. Nevertheless, we detected in most participants A(H5)-reactive antibodies with Fc-effector functions, likely directed at the conserved HA stalk. Additionally, we observed abundant neuraminidase (NA) inhibiting antibodies against avian N1s and T-cell responses against HAs and NAs from A(H5) influenza viruses. These responses correlated strongly with immune responses targeting an A(H1N1) seasonal influenza virus, indicating they were likely induced by prior exposures.

Interpretation.

Together, our findings suggest that partial cross-reactive immunity to A(H5) influenza viruses exists in humans, which may play an important role during future outbreaks, potentially by blunting disease severity. Characterizing such baseline immunity is crucial for accurate pandemic risk assessment and preparedness planning.

Funding.

Netherlands Organization for Health Research and Development (ZonMw), European Union EU4Health program DURABLE, Dutch Ministries of Agriculture, Fisheries, Food Security and Nature and Health, Welfare and Sport, National Institute of Health - National Institute of Allergies and Infectious Diseases (NIH-NIAID). The funding sources had no role in study design, data collection, analysis, interpretation of the data, or the decision to submit the paper for publication.

Competing Interest Statement

A.S. is a consultant for Alcimed, Arcturus, Darwin Health, Desna Therapeutics, EmerVax, Gilead Sciences, Guggenheim Securities, Link University, and RiverVest Venture Partners. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. The remaining authors declare no competing interests.

Funding Statement

The study was funded by the Netherlands Organization for Health Research and Development (ZonMw, NCOH Pandemic Preparedness Research Kickstarter, grant agreement 10710022210003), European Union EU4Health program DURABLE (grant number 101102733), and the Dutch Ministries of Agriculture, Fisheries, Food Security and Nature and Health, Welfare and Sport. This project has been additionally funded with Federal funds from the National Institute of Health - National Institute of Allergies and Infectious Diseases (NIH-NIAID) contract no.75N93024C00056 and 75N93021C00014. The funding sources had no role in study design, data collection, analysis, interpretation of the data, or the decision to submit the paper for publication.

Source: MedRxIV, https://www.medrxiv.org/content/10.1101/2025.07.31.25331995v1

____

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...

ETIDIOH - NEW

Search This Blog